Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pirenoxine→

Pirenoxine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1043-21-6
Molecular formula
C16H8N2O5
Molecular weight
308.24 g/mol
Drug class
Ophthalmic anti-cataract agentquinone-opacification inhibitor
Mechanism of action
Competes with quinone compounds implicated in oxidation and insolubilisation of water-soluble lens proteins. It is intended to maintain lens protein solubility and retard progression of early lens opacity; evidence of clinical benefit is limited and product use is jurisdiction-specific.
Indications / reported uses
  • Topical ophthalmic treatment intended to retard progression of early senile cataract in Japan and selected Asian markets; this is not a treatment for advanced cataract or a substitute for surgery.

Sources: https://www.rad-ar.or.jp/siori/english/search/result?n=1575 · https://www.kegg.jp/medicus-bin/japic_med?japic_code=00069142 · https://www.data-index.co.jp/medsearch/ethicaldrugs/searchresult/detail/?trk_toroku_code=1319706Q3043 · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ophthalmic anti-cataract agent; quinone-opacification inhibitor

Mechanism of action

Competes with quinone compounds implicated in oxidation and insolubilisation of water-soluble lens proteins. It is intended to maintain lens protein solubility and retard progression of early lens opacity; evidence of clinical benefit is limited and product use is jurisdiction-specific.

General use cases

  • Topical ophthalmic treatment intended to retard progression of early senile cataract in Japan and selected Asian markets; this is not a treatment for advanced cataract or a substitute for surgery.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Pirenoxine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pirenoxine Permitted Daily Exposure (PDE) report (the Pirenoxine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pirenoxine Occupational Exposure Limit (OEL) report (the Pirenoxine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.